FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145396414> ?p ?o ?g. }

• W2145396414 endingPage "176" @default.
• W2145396414 startingPage "169" @default.
• W2145396414 abstract "Objective. The aim of this study was to investigate the role of apoptosis during progestin therapy for the treatment of endometrial hyperplasia. Methods. Pre- and posttreatment paraffin-embedded endometrial tissue samples from 19 women with endometrial hyperplasia were examined for changes in glandular cellularity and apoptotic activity related to the administration of progestins. Twelve patients were successfully treated with progestin therapy and 7 patients failed treatment. Glandular cellularity was assessed based on calculating the average number of cells per gland obtained on histologic examination of hematoxylin and eosin stained tissue sections. Apoptotic activity was assessed on the same tissue sections by counting the average number of apoptotic cells per 10 high power fields (hpf) using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The effects of progesterone on apoptotic activity in a low-grade endometrial adenocarcinoma cell line (Ishikawa cells) was also examined using an ELISA cell death detection kit. Results. Glandular cellularity significantly decreased with progestin therapy in both treatment outcome groups. The reduction in cells per gland was significantly greater in the group of successfully treated cases compared to the treatment failures (P = 0.005). However, within the successfully treated group, in situ detection of apoptotic cells using the TUNEL assay showed no statistical difference between pre- and posttreatment endometrial samples. Interestingly, a significant decrease in apoptosis was found in posttreatment samples of the group with persistent hyperplasia. The average number of apoptotic cells detected in 10 hpf was reduced from 7.9 prior to treatment to 3.1 after progestin therapy (P = 0.03). In the progesterone-treated Ishikawa cell line, an increase in apoptotic activity started at 24 h, reached a peak at 48 h, and continued up to 72 h of hormone treatment. At 48 h, apoptotic activity was 42.6% greater than in the untreated control (P = 0.04). By 72 h of progesterone treatment, apoptosis was 37.2% greater in the treated cells compared to the noninoculated cells (P = 0.04). Conclusions. Progestin-induced apoptosis may occur during the early period of treatment for endometrial hyperplasia. Compared to the fully responsive group, persistent endometrial hyperplasia may have intrinsically different molecular mechanisms in response to progestin therapy." @default.
• W2145396414 created "2016-06-24" @default.
• W2145396414 creator A5032096394 @default.
• W2145396414 creator A5043805914 @default.
• W2145396414 creator A5045578093 @default.
• W2145396414 creator A5051738977 @default.
• W2145396414 creator A5053540007 @default.
• W2145396414 date "2000-11-01" @default.
• W2145396414 modified "2023-09-28" @default.
• W2145396414 title "Apoptosis May Be an Early Event of Progestin Therapy for Endometrial Hyperplasia" @default.
• W2145396414 cites W1560674775 @default.
• W2145396414 cites W1969236558 @default.
• W2145396414 cites W1991865867 @default.
• W2145396414 cites W1992111987 @default.
• W2145396414 cites W2014795587 @default.
• W2145396414 cites W2017946505 @default.
• W2145396414 cites W2027486582 @default.
• W2145396414 cites W2035086662 @default.
• W2145396414 cites W2049554571 @default.
• W2145396414 cites W2050251876 @default.
• W2145396414 cites W2062302986 @default.
• W2145396414 cites W2064617101 @default.
• W2145396414 cites W2071251506 @default.
• W2145396414 cites W2071412836 @default.
• W2145396414 cites W2085486507 @default.
• W2145396414 cites W2093103847 @default.
• W2145396414 cites W2093957373 @default.
• W2145396414 cites W2104890635 @default.
• W2145396414 cites W2130189546 @default.
• W2145396414 cites W2152374768 @default.
• W2145396414 cites W2152487546 @default.
• W2145396414 cites W2186183020 @default.
• W2145396414 cites W2190894843 @default.
• W2145396414 cites W2335854637 @default.
• W2145396414 cites W4233484287 @default.
• W2145396414 cites W4245339471 @default.
• W2145396414 doi "https://doi.org/10.1006/gyno.2000.5955" @default.
• W2145396414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11063639" @default.
• W2145396414 hasPublicationYear "2000" @default.
• W2145396414 type Work @default.
• W2145396414 sameAs 2145396414 @default.
• W2145396414 citedByCount "54" @default.
• W2145396414 countsByYear W21453964142012 @default.
• W2145396414 countsByYear W21453964142013 @default.
• W2145396414 countsByYear W21453964142014 @default.
• W2145396414 countsByYear W21453964142015 @default.
• W2145396414 countsByYear W21453964142016 @default.
• W2145396414 countsByYear W21453964142017 @default.
• W2145396414 countsByYear W21453964142019 @default.
• W2145396414 countsByYear W21453964142021 @default.
• W2145396414 countsByYear W21453964142022 @default.
• W2145396414 countsByYear W21453964142023 @default.
• W2145396414 crossrefType "journal-article" @default.
• W2145396414 hasAuthorship W2145396414A5032096394 @default.
• W2145396414 hasAuthorship W2145396414A5043805914 @default.
• W2145396414 hasAuthorship W2145396414A5045578093 @default.
• W2145396414 hasAuthorship W2145396414A5051738977 @default.
• W2145396414 hasAuthorship W2145396414A5053540007 @default.
• W2145396414 hasConcept C125473707 @default.
• W2145396414 hasConcept C126322002 @default.
• W2145396414 hasConcept C126894567 @default.
• W2145396414 hasConcept C134018914 @default.
• W2145396414 hasConcept C142724271 @default.
• W2145396414 hasConcept C154113507 @default.
• W2145396414 hasConcept C16685009 @default.
• W2145396414 hasConcept C190283241 @default.
• W2145396414 hasConcept C196795494 @default.
• W2145396414 hasConcept C204232928 @default.
• W2145396414 hasConcept C2775904963 @default.
• W2145396414 hasConcept C2776607906 @default.
• W2145396414 hasConcept C2777164284 @default.
• W2145396414 hasConcept C2777562237 @default.
• W2145396414 hasConcept C2777689261 @default.
• W2145396414 hasConcept C2779742232 @default.
• W2145396414 hasConcept C31573885 @default.
• W2145396414 hasConcept C55493867 @default.
• W2145396414 hasConcept C71924100 @default.
• W2145396414 hasConcept C86803240 @default.
• W2145396414 hasConceptScore W2145396414C125473707 @default.
• W2145396414 hasConceptScore W2145396414C126322002 @default.
• W2145396414 hasConceptScore W2145396414C126894567 @default.
• W2145396414 hasConceptScore W2145396414C134018914 @default.
• W2145396414 hasConceptScore W2145396414C142724271 @default.
• W2145396414 hasConceptScore W2145396414C154113507 @default.
• W2145396414 hasConceptScore W2145396414C16685009 @default.
• W2145396414 hasConceptScore W2145396414C190283241 @default.
• W2145396414 hasConceptScore W2145396414C196795494 @default.
• W2145396414 hasConceptScore W2145396414C204232928 @default.
• W2145396414 hasConceptScore W2145396414C2775904963 @default.
• W2145396414 hasConceptScore W2145396414C2776607906 @default.
• W2145396414 hasConceptScore W2145396414C2777164284 @default.
• W2145396414 hasConceptScore W2145396414C2777562237 @default.
• W2145396414 hasConceptScore W2145396414C2777689261 @default.
• W2145396414 hasConceptScore W2145396414C2779742232 @default.
• W2145396414 hasConceptScore W2145396414C31573885 @default.
• W2145396414 hasConceptScore W2145396414C55493867 @default.
• W2145396414 hasConceptScore W2145396414C71924100 @default.
• W2145396414 hasConceptScore W2145396414C86803240 @default.

• next